Method for reconstructing interdental papilla using hyaluronic acid

Abstract

To provide: a method for reconstructing an interdental papilla that has disappeared or receded in a simple manner; a method for reconstructing an interdental papilla that can effectively reconstruct the interdental papilla without pain or side effects; and a method for reconstructing an interdental papilla that is highly useful as a rescue treatment capable of promptly resolving unexpected gingival recession or interdental papilla loss occurring during dental treatment.SOLUTION: A method for reconstructing an interdental papilla includes an administration step of administering, to gingiva, a composition containing hyaluronic acid or a pharmaceutically acceptable salt thereof, where the composition includes a composition with a complex viscosity of 250 Pa s to 850 Pa s.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a method for reconstructing interdental papillae using hyaluronic acid. [Background technology]

[0002] The interdental papilla is the part of the free gingiva that occupies the space between two adjacent teeth and allows the free gingival margin to continue from the dental arch in a festoon pattern.

[0003] The interdental papillae firmly support the teeth, maintaining their stability and preventing food particles and foreign objects from getting trapped between the teeth. They also fill the gaps between the teeth, providing an aesthetic function by creating a natural, balanced smile.

[0004] Interdental papillae can disappear due to abnormal tooth shape, inappropriate restorations, inappropriate oral hygiene management methods, periodontal disease, etc. When interdental papillae disappear or recede, the so-called black triangle (black triangle syndrome or receding interincisal papilla) occurs, causing the various functional and aesthetic problems mentioned above.

[0005] To date, methods to resolve the problem of interdental papilla loss have included gingival regeneration surgery, which involves transplanting gingival tissue, resin filling, which fills the spaces between teeth with resin, prosthetic adjustments to narrow the gaps between teeth using crowns and bridges, and orthodontic treatment. However, the methods of reconstructing interdental papilla known to date are not only complicated and painful, taking a long time to regenerate the interdental papilla, and incurring high treatment costs, but also have inherent limitations in that the effectiveness of reconstructing interdental papilla is limited, leading to their neglect by patients. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Korean Patent Registration No. 10-1457231 (2014.10.27.) [Patent Document 2] Korean Patent Publication No. 10-2018-0020727 (2018.02.28.) Summary of the Invention [Problem to be solved by the invention]

[0007] It is an object of the present invention in one aspect to reconstruct lost or receding interdental papillae.

[0008] An object of the present invention in one aspect is to eliminate black triangles.

[0009] An object of the present invention in one aspect is to reconstruct the interdental papilla and remove the black triangle in a simple manner.

[0010] An object of one aspect of the present invention is to provide a method for reconstructing interdental papillae without side effects.

[0011] An object of one aspect of the present invention is to provide a composition for interdental papilla reconstruction that reduces pain that occurs upon administration (injection).

[0012] An object of the present invention in one aspect is to reconstruct interdental papillae in a simpler and more economical manner than conventional surgical methods.

[0013] It is an object of the present invention in one aspect to augment (increase in quantity and volume) the soft tissue of the interdental papilla.

[0014] It is an object of the present invention in one aspect to promote lateral (horizontal thickness) and longitudinal (vertical height) growth of the interdental papilla.

[0015] It is an object of the present invention in one aspect to facilitate the creeping attachment phenomenon.

[0016] The problems to be solved by the embodiments are not limited to these, and may also include the means for solving the problems described below and the objectives and effects that can be grasped from the embodiments. [Means for solving the problem]

[0017] To achieve the above object, in one aspect, the present invention provides a method for reconstructing interdental papilla.

[0018] Furthermore, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing interdental papilla, the method comprising administering to the gums a composition containing hyaluronic acid or a pharmaceutically acceptable salt thereof, the composition comprising a composition having a complex viscosity of 250 Pa·s to 850 Pa·s.

[0019] Furthermore, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing interdental papilla, wherein the administration step includes administering 0.005 cc to 0.05 cc of the composition.

[0020] Furthermore, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing interdental papilla, wherein the administration step comprises administering the composition in an amount of 0.001 cc to 0.01 cc once to ten times.

[0021] In the above aspect of the present invention, the administering step may comprise administering the composition to a patient in an amount of 0.1 mm 2 ~4mm 2 and administering to the gingiva an amount of 100 mg / kg of gingiva in an area of ​​100 mg / kg of the gingiva.

[0022] In addition, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing interdental papilla, wherein the composition comprises a gel formulation.

[0023] Furthermore, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing an interdental papilla, wherein the interdental papilla reconstruction rate represented by the following mathematical formula (A) is 70% or more.

[0024]

number

[0025] Furthermore, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing interdental papilla, which comprises administering the composition using a 25G to 35G needle.

[0026] Furthermore, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing an interdental papilla, wherein the administration step comprises administering the composition to a site 1 mm to 3 mm below the apex of the interdental papilla.

[0027] In addition, in the above aspect of the present invention, there is provided a method for reconstructing an interdental papilla, which further comprises a molding step.

[0028] Furthermore, in the above-mentioned aspect of the present invention, there is provided a method for reconstructing interdental papilla, which comprises carrying out the method at intervals of 2 to 4 weeks.

[0029] In addition, in the above-mentioned aspect of the present invention, there is provided a kit for interdental papilla reconstruction, comprising a composition containing hyaluronic acid or a pharmaceutically acceptable salt thereof, and a procedure manual describing the method for reconstructing the interdental papilla. [Effects of the Invention]

[0030] The method for reconstructing interdental papillae according to one aspect of the present invention allows for the reconstruction of lost or receding interdental papillae more easily than conventional treatment methods. Furthermore, the method for reconstructing interdental papillae according to one aspect of the present invention allows for the effective reconstruction of interdental papillae without pain or side effects. Furthermore, the method for reconstructing interdental papillae according to the present invention is highly useful as a rescue treatment that can quickly resolve unexpected gingival recession or loss of interdental papillae during dental treatment.

[0031] The various beneficial advantages and effects of the present invention are not limited to the above, but will be more easily understood in the course of describing specific embodiments of the present invention. [Brief explanation of the drawings]

[0032] [Figure 1] FIG. 1 shows the complex viscosity of the hyaluronic acid gel contained in the composition and the rate of interdental papilla reconstruction (%) over time. [Figure 2] FIG. 1 is a graph showing the interdental papilla reconstruction rate (%) over time and the administered amount of the composition. [Figure 3] FIG. 1 shows the administration position and administration area of ​​the composition (a black-framed square with a black dot in the center indicates the administration position (dot) and administration area). DETAILED DESCRIPTION OF THE INVENTION

[0033] The present invention can be modified in various ways and can have various embodiments, so that the present invention will be described by illustrating specific embodiments, but it should be understood that this does not limit the present invention to the specific embodiments, and includes all modifications, equivalents, and alternatives that fall within the spirit and technical scope of the present invention.

[0034] Furthermore, the terms or words used in the specification and claims of the present invention should not be interpreted as being limited to their ordinary or dictionary meanings, but should be interpreted as meanings and concepts that fit the technical idea of ​​the present invention, based on the principle that an inventor can appropriately define the concept of a term in order to best explain his or her invention.

[0035] Terms including ordinal numbers such as second, first, etc. may be used to describe various components, but the components are not limited by these terms. These terms are used only to distinguish one component from another. For example, a second component can be designated as a first component, and similarly, a first component can be designated as a second component, without departing from the scope of the present invention. The term "and / or" includes a combination of multiple associated listed items or any one item of multiple associated listed items.

[0036] Furthermore, the terms used in this application are merely used to describe specific embodiments and are not intended to limit the present invention. The singular expressions include the plural expressions unless the context clearly dictates otherwise. It should be understood that in this application, terms such as "comprise" or "have" specify the presence of features, numbers, steps, operations, components, parts, or combinations thereof described in the specification, and do not preclude the possibility of the presence or addition of one or more other features, numbers, steps, operations, components, parts, or combinations thereof.

[0037] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the art to which this invention belongs. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning they have in the context of the relevant art, and should not be interpreted as idealized or overly formal unless explicitly defined herein.

[0038] The present invention will be described in detail below.

[0039] In one aspect, the present invention is a method for reconstructing an interdental papilla.

[0040] In one aspect, the present invention is a method for reconstructing interdental papillae, comprising a composition administration step of administering a composition containing hyaluronic acid or a pharmaceutically acceptable salt thereof to the gums, wherein the composition has a complex viscosity of 200 Pa·s to 850 Pa·s.

[0041] Hyaluronic acid is a sulfur-free polymer belonging to the glycosaminoglycan family, which is ubiquitous in mammalian tissues, has an unbranched structure, and is composed of regularly repeating disaccharide units consisting of glucuronic acid and N-acetylglucosamine.

[0042] Hyaluronan is highly variable in size, exceeding 1,000 kDa and reaching 3,000 to 9,000 kDa daltons in some tissues.

[0043] In the present invention, hyaluronic acid may be used as it is, or may be used after being salted with various salts such as sodium.

[0044] As used herein, the term "pharmaceutically acceptable salt" includes all salts of a compound that are physiologically acceptable to a subject or target object. A pharmaceutically acceptable salt is preferably a formulation of a compound that does not cause significant irritation to the organism to which the compound is administered and does not impair the biological activity and physical properties of the compound. The pharmaceutically acceptable salt may include acid addition salts formed with acids that form non-toxic acid addition salts containing pharmaceutically acceptable anions, such as inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, and hydroiodic acid; organic carboxylic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, and salicylic acid; and sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.

[0045] If the molecular weight of the hyaluronic acid or its pharmaceutically acceptable salt is less than 500 kDa, it may cause dermatitis, and if the molecular weight of the hyaluronic acid or its sodium salt is more than 3,000 kDa, it is undesirable because the molecular weight is too large and it becomes difficult to properly administer it to the gingival connective tissue layer.

[0046] In one embodiment, the molecular weight of the hyaluronic acid or a pharmaceutically acceptable salt thereof may be 1,000 kDa to 3,000 kDa, or 1,300 kDa to 2,500 kDa, or 1,300 kDa to 2,300 kDa, or 1,500 kDa to 2,000 kDa.

[0047] In one embodiment, the composition may include a composition having a complex viscosity of 200 Pa·s to 850 Pa·s. Specifically, the complex viscosity of the composition may be 200 Pa·s or more, or 250 Pa·s or more, or 300 Pa·s or more, or 350 Pa·s or more, or 400 Pa·s or more, or 450 Pa·s or more, or 500 Pa·s or more, or 550 Pa·s or more, or 600 Pa·s or more, or 610 Pa·s or more, or 630 Pa·s or more, or 650 Pa·s or more, or 6 It may be 70 Pa·s or more, or 690 Pa·s or more, or 700 Pa·s or more, or 710 Pa·s or more, or 720 Pa·s or more, or 730 Pa·s or more, or 740 Pa·s or more, or 750 Pa·s or more, or 760 Pa·s or more, or 770 Pa·s or more, or 780 Pa·s or more, or 790 Pa·s or more, or 800 Pa·s or more, or 850 Pa·s or more or 840 Pa·s or less, or 830 Pa·s or less, or 820 Pa·s or less, or 810 Pa·s or less, or 800 Pa·s or less, or 790 Pa·s or less, or 780 Pa·s or less, or 770 Pa·s or less, or 760 Pa·s or less, or 750 Pa·s or less, or 740 Pa·s or less, or 730 Pa·s or less, or 720 Pa·s or less, or 710 It may be Pa·s or less, or 700 Pa·s or less, or 690 Pa·s or less, or 670 Pa·s or less, or 650 Pa·s or less, or 630 Pa·s or less, or 610 Pa·s or less, or 600 Pa·s or less, or 550 Pa·s or less, 500 Pa·s or less, 450 Pa·s or less, 400 Pa·s or less, 350 Pa·s or less, 300 Pa·s or less, or 250 Pa·s or less.

[0048] In the above aspect, the complex viscosity of the composition may be 200 Pa·s to 850 Pa·s, or 300 Pa·s to 850 Pa·s, or 400 Pa·s to 850 Pa·s, or 500 Pa·s to 850 Pa·s, or 500 Pa·s to 800 Pa·s, or 500 Pa·s to 750 Pa·s, or 550 Pa·s to 750 Pa·s, or 570 Pa·s to 750 Pa·s, or 570 Pa·s to 730 Pa·s, or 590 Pa·s to 730 Pa·s, or 600 Pa·s to 710 Pa·s, or 601 Pa·s to 700 Pa·s.

[0049] The term "administration" as used herein means introducing individual components of a therapy for treatment or improvement of a condition by an appropriate method, and the administration route can be various routes, such as oral or parenteral, as long as the target site (tissue, blood vessel, muscle, organ, body cavity, etc.) can be reached. The term "administration" is used as a concept that includes all methods by which individual components, compositions, etc. for treatment or improvement of a condition can be delivered to the target tissue, such as infusion, injection, medication, infusion, ingestion, coating, or application.

[0050] In one embodiment, the composition used for one treatment may be administered at once or in multiple doses. In one embodiment, the composition may include, but is not limited to, an injectable composition. For example, the composition may be formulated as an injection, a suspension, or an external preparation.

[0051] In one embodiment, when the composition is administered by injection, the administration method can be determined taking into consideration the condition of the recipient, the area of ​​the administration site, etc. Examples of administration methods that can be used include, but are not limited to, a linear injection method in which an injection needle is inserted and then the composition is injected linearly while slowly withdrawing the needle, a point injection method in which the composition is administered in several small dots, a retrograde injection method in which the needle is inserted deeply and then injected while being withdrawn, a cross-hatching injection method in which the composition is injected in a grid pattern by crisscrossing linear injection methods, a fan injection method in which a needle is inserted once and then moved in various directions to inject the composition in a fan shape, and a microcannula injection method in which the composition is administered using a cannula with a blunt tip instead of a needle.

[0052] The composition may have any formulation selected from the group consisting of injections (sterile aqueous solutions), suspensions, and external preparations, and may also be various parenteral formulations.

[0053] When the composition is formulated, it may contain diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants, as used in the art. For example, when the composition is formulated as an injection, it may be prepared using an aqueous solvent such as saline, or a non-aqueous solvent such as vegetable oil, higher fatty acid ester, or alcohols such as ethanol, benzyl alcohol, or glycerin. The composition may also contain pharmaceutical carriers such as stabilizers, such as ascorbic acid and EDTA, to prevent deterioration of the formulation, emulsifiers, crosslinkers, such as BDDE (1,4-butanediol diglycidyl ether), buffers for pH adjustment, and preservatives, such as cresol and benzyl alcohol, to control microbial growth (e.g., phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).

[0054] In one embodiment, the injection may contain hyaluronic acid or a pharmaceutically acceptable salt thereof, NaOH, BDDE, etc. The dosage of components other than hyaluronic acid or a pharmaceutically acceptable salt thereof contained in the injection may be appropriately adjusted according to protocols known in the art for injections containing hyaluronic acid or a pharmaceutically acceptable salt thereof.

[0055] In one embodiment, the concentration of the hyaluronic acid or a pharmaceutically acceptable salt thereof may be 0.1% to 10% (1 mg / ml to 100 mg / ml), or 1% to 5% (10 mg / ml to 50 mg / ml), or 1% to 3% (10 mg / ml to 30 mg / ml), or 1.5% to 2.5% (15 mg / ml to 25 mg / ml).

[0056] In one embodiment, when the composition is formulated as a suspension, vegetable oils such as propylene glycol, polyethylene glycol, injectable esters such as ethyl oleate, and the like can be used.

[0057] In one embodiment, when the composition is formulated as an external preparation, it can be formulated into a solid, semi-solid, or liquid form by adding inorganic or organic carriers, excipients, and diluents. For example, the external preparation may include an external skin preparation having a transdermal administration type formulation such as an ointment, lotion, gel, cream, patch, spray, suspension, and emulsion.

[0058] In one aspect, when the viscosity of the composition is as described above, the composition can achieve optimal spreading within the interdental papilla and the effect of reconstructing the interdental papilla. For example, when the viscosity of the composition exceeds the above range, the viscosity may be too high, making it difficult to administer the composition into the interdental papilla, and there may be a limit to the composition's spreading within the interdental papilla even after administration.

[0059] In one embodiment, the composition administration step may include administering 0.005 cc to 0.05 cc of the composition.

[0060] In one aspect, the amount of composition administered in the composition administering step may be 0.005 cc or more, or 0.006 cc or more, or 0.007 cc or more, or 0.008 cc or more, or 0.009 cc or more, or 0.01 cc or more, or 0.011 cc or more, or 0.013 cc or more, or 0.015 cc or more, or 0.017 cc or more, or 0.019 cc or more, or 0.02 cc or more, or 0.021 cc It may be 0.022cc or more, or 0.023cc or more, or 0.024cc or more, or 0.025cc or more, or 0.026cc or more, or 0.027cc or more, or 0.028cc or more, or 0.029cc or more, or 0.03cc or more, or 0.035cc or more, or 0.040cc or more, or 0.045cc or more, or it may be 0.05cc or less, or 0.049cc or less, or 0. 0.047cc or less, or 0.045cc or less, or 0.043cc or less, or 0.041cc or less, or 0.040cc or less, or 0.039cc or less, or 0.037cc or less, or 0.035cc or less, or 0.033cc or less, or 0.031cc or less, or 0.030cc or less, or 0.029cc or less, or 0.028cc or less, or 0.027cc or less, or 0.026cc or less, or 0.025cc or less , or 0.024cc or less, or 0.023cc or less, or 0.022cc or less, or 0.021cc or less, or 0.020cc or less, or 0.019cc or less, or 0.017cc or less, or 0.015cc or less, or 0.013cc or less, or 0.011cc or less, or 0.010cc or less, or 0.009cc or less, or 0.008cc or less, or 0.007cc or less, or 0.006cc or less.

[0061] In one aspect, if the composition is administered in an amount less than the dose described above, it is difficult to expect an interdental papilla reconstruction effect, and if administered in excess, side effects such as pressure pain, foreign body sensation due to excessive increase in the volume of the interdental papilla area, and external leakage of the composition may occur.

[0062] In one embodiment, the composition administration step may include administering 0.001 cc to 0.01 cc of the composition 1 to 10 times.

[0063] In one embodiment, the amount of the composition administered at one time (hereinafter referred to as the dose per time) may be 0.001 cc to 0.01 cc, and in another embodiment, the amount of the composition administered at one time is 0.001 cc or more, or 0.0015 cc or more, or 0.002 cc or more, or 0.0025 cc or more, or 0.003 cc or more, or 0.0035 cc or more, or 0.004 cc or more, or 0.0041 cc or more, or 0.0042cc or more, or 0.0043cc or more, or 0.0044cc or more, or 0.0045cc or more, or 0.0046cc or more, or 0.0047cc or more, or 0.0048cc or more, or 0.0049cc or more, or 0.005cc or more, or 0.0055cc or more, or 0.006cc or more, or 0.0065cc or more, or 0.007cc or more, or 0.0075cc or more, or 0 It may be 0.008cc or more, or 0.0085cc or more, or 0.009cc or more, or 0.0095cc or more, or 0.01cc or less, or 0.009cc or less, or 0.0085cc or less, or 0.0080cc or less, or 0.0075cc or less, or 0.0070cc or less, or 0.0065cc or less, or 0.0060cc or less, or 0.0059cc or less, or 0.00 It may be 58cc or less, or 0.0057cc or less, or 0.0056cc or less, or 0.0055cc or less, or 0.0054cc or less, or 0.0053cc or less, or 0.0052cc or less, or 0.0051cc or less, or 0.005cc or less, or 0.0045cc or less, or 0.0040cc or less, or 0.0035cc or less, or 0.0030cc or less, or 0.0025cc or less.

[0064] In one embodiment, the composition administration step may include administering the composition 1 to 10 times when administering the composition at the single dose.

[0065] In one aspect, the step of administering the composition may include administering the composition in the single dosage amount 1 or more, or 2 or more, or 3 or more, or 4 or more, or 5 or more, or 6 or more, or 7 or more, or 8 or more, or 9 or more times, or 10 or less, or 9 or less, or 8 or less, or 7 or less, or 6 or less, or 5 or less, or 4 or less, or 3 or less, or 2 or less.

[0066] In one aspect, when the amount administered per administration in the composition administration step is 0.001 cc to 0.01 cc, the number of administrations may be 1 to 10 times, or 2 to 8 times, or 3 to 7 times, or 4 to 6 times.

[0067] In one embodiment, the amount administered per administration in the composition administration step may be 0.003 cc to 0.007 cc, and in this case, the number of administrations may be 3 to 7 times, or 4 to 6 times, or 5 times.

[0068] In one embodiment, the composition administration step comprises administering the composition to a patient in a volume of 0.1 mm. 2 ~4mm 2 The method may include administering to the gums in an area of ​​100 mm.

[0069] In one embodiment, the area of ​​the gingiva to which the composition is administered in the composition administration step is 0.01 mm 2 It may be more than 0.05 mm 2 or more, or 0.1 mm 2 or more, or 0.15 mm 2 or more, or 0.20 mm 2 or more, or 0.25 mm 2 or more, or 0.30 mm 2 or more, or 0.35 mm 2 or more, or 0.40 mm 2 or more, or 0.45 mm 2 or more, or 0.50 mm 2 or more, or 0.55 mm 2 or more, or 0.60 mm 2 or more, or 0.65 mm 2or more than 0.70 mm 2 or more, or 0.75 mm 2 or more, or 0.80 mm 2 or more, or 0.81 mm 2 or more, or 0.83 mm 2 or more, or 0.85 mm 2 or more, or 0.87 mm 2 or more, or 0.89 mm 2 or more, or 0.90 mm 2 or more, or 0.91 mm 2 or more, or 0.92 mm 2 or more, or 0.93 mm 2 or more, or 0.94 mm 2 or more, or 0.95 mm 2 or more, or 0.96 mm 2 or more, or 0.97 mm 2 or more, or 0.98 mm 2 or more, or 0.99 mm 2 or more, or 1.0 mm 2 or more, or 1.5 mm 2 or more, or 2.0 mm 2 or more, or 2.5 mm 2 or more, or 3.0 mm 2 or more, or 3.5 mm 2 It may be 4.0 mm or more 2 Less than or equal to 3.5 mm 2 Less than or equal to 3.0 mm 2 Less than or equal to 2.5 mm 2 or less than 2.0 mm 2 Less than or equal to 1.9 mm 2 Less than or equal to 1.8 mm 2 Less than or equal to 1.7 mm 2 Less than or equal to 1.6 mm 2 Less than or equal to 1.5 mm 2 Less than or equal to 1.47 mm 2 Less than or equal to 1.45 mm 2 Less than or equal to 1.43 mm 2 Less than or equal to 1.41 mm 2 Less than or equal to 1.4 mm 2 Less than or equal to 1.37 mm 2 Less than or equal to 1.35 mm 2 Less than or equal to 1.33 mm 2Less than or equal to 1.31 mm 2 Less than or equal to 1.3mm 2 Less than or equal to 1.27 mm 2 Less than or equal to 1.25 mm 2 Less than or equal to 1.23 mm 2 Less than or equal to 1.21 mm 2 Less than or equal to 1.2 mm 2 Less than or equal to 1.19 mm 2 Less than or equal to 1.17 mm 2 Less than or equal to 1.15 mm 2 Less than or equal to 1.13 mm 2 Less than or equal to 1.1 mm 2 Less than or equal to 1.0 mm 2 or less than 0.9 mm 2 or less than 0.8 mm 2 or less than 0.7 mm 2 Less than or equal to 0.6 mm 2 Less than or equal to 0.5 mm 2 or less than 0.4 mm 2 Less than or equal to 0.3mm 2 or less than 0.2 mm 2 or less than 0.1 mm 2 Less than or equal to 0.09 mm 2 or less than 0.07 mm 2 Less than or equal to 0.05 mm 2 Less than or equal to 0.03 mm 2 or less than 0.02 mm 2 It may be the following:

[0070] In one embodiment, the area of ​​the gum to which the composition is administered is 0.5 mm 2 ~3.0mm 2 or 0.5 mm 2 ~2.5mm 2 , or 0.5 mm 2 ~2.0mm 2 , or 0.5 mm 2 ~1.5mm 2 , or 0.7 mm 2 ~1.3mm 2 , or 0.8 mm 2 ~1.2mm 2 may be.

[0071] In one embodiment, when the area of ​​the gum to which the composition is administered is within the above range, an excellent rate of interdental papilla reconstruction can be obtained.

[0072] In one embodiment, the composition may comprise a gel formulation.

[0073] In one embodiment, the method may be such that the interdental papilla reconstruction rate, expressed by the following mathematical formula (A), is 70% or more.

[0074]

number

[0075] (Black triangle: A black triangular space between teeth that occurs when the interdental papilla disappears or recedes)

[0076] In one aspect, when using the method for reconstructing interdental papilla of the present invention, the reconstructed rate of interdental papilla may be 70% or more, or 71% or more, or 72% or more, or 73% or more, or 74% or more, or 75% or more, or 76% or more, or 77% or more, or 78% or more, or 79% or more, or 80% or more, or 85% or more, or 90% or more, or 95% or more.

[0077] In one embodiment, the composition may be administered using a 25G to 35G needle. In one embodiment, the composition may be administered using a 30G needle.

[0078] When the injection needle has the above thickness, the composition of the above viscosity can be easily administered while minimizing pain to the patient.

[0079] In one embodiment, the composition may be administered using a syringe equipped with an autoinjector.

[0080] In one embodiment, the composition administration step may include administering the composition to a site 1 mm to 3 mm below the apex of the interdental papilla.

[0081] In one embodiment, the composition may be administered at a site 2 mm to 3 mm below the apex of the interdental papilla.

[0082] In one embodiment, the method may further comprise a molding step.

[0083] In one embodiment, the molding may refer to shaping or preparing the site where the composition has been administered using hands, an instrument, or the like.

[0084] In one embodiment, the molding step may occur after the administering step.

[0085] In one embodiment, the molding may be used to adjust the proper placement of the administered composition at the target administration location, for example, to correct any hardening or protrusion of the administered composition within the administration site, or to distribute the administered composition evenly within the administration site to create a natural-looking gum line.

[0086] In one aspect, the molding may be achieved by massaging. The massaging may involve applying gentle pressure with the hands or the like so that the composition injected into the administration site is naturally positioned within the administration site. In one aspect, the composition can be flattened or stretched within the administration site by massaging.

[0087] In one embodiment, the method for reconstructing the interdental papilla may be performed at intervals of 2 to 4 weeks.

[0088] The method for reconstructing interdental papillae may further include procedures generally known to those skilled in the art for reconstructing interdental papillae or dental treatment, such as oral disinfection, anesthesia, ankle massage, massage, etc.

[0089] The present invention also provides a kit for interdental papilla reconstruction, which includes a composition containing hyaluronic acid or a pharmaceutically acceptable salt thereof, and a procedure manual describing the method for reconstructing the interdental papilla.

[0090] The instructions may include information such as the complex viscosity, dosage unit area, single dosage, number of dosages, and other precautions of the composition containing hyaluronic acid or a pharmaceutically acceptable salt thereof.

[0091] In one embodiment, the composition containing hyaluronic acid or a pharmaceutically acceptable salt thereof in the kit may be packaged in a container or vessel, and the hyaluronic acid or a pharmaceutically acceptable salt thereof may be packaged in a solid form (e.g., a lyophilized powder) or a liquid form, but is not limited thereto.

[0092] In one embodiment, the composition may be filled in a container with each component contained in the composition. The kit may further include an anesthetic, an anti-inflammatory agent, a pH adjuster, etc. in addition to the composition. These may be filled individually in containers separate from the container in which the composition is filled.

[0093] The kit may also include an administration device for delivering the composition to the point of administration. In one embodiment, the administration device may be, but is not limited to, a syringe.

[0094] The present invention will be described in detail below through the following embodiments. These examples are merely for the purpose of illustrating the present invention, and the scope of the present invention is not limited to these examples.

[0095] Confirmation of interdental papilla reconstruction rate by complex viscosity of hyaluronic acid gel

[0096] Using a 30G needle (syringe) equipped with an auto-injector, the hyaluronic acid gel listed in Table 1 was administered five times in 0.005cc doses (total 0.025cc) to a location 2mm to 3mm from the apex of the subject's interdental papilla, and the rate of interdental papilla reconstruction was then confirmed over time.

[0097] [Table 1]

[0098] As a result, for test numbers 1 to 6, the rate of interdental papilla reconstruction increased in proportion to the time elapsed after administration. It was also confirmed that for test numbers 1 to 6, the rate of interdental papilla reconstruction increased in proportion to the complex viscosity (see Figure 1).

[0099] On the other hand, when the complex viscosity exceeded 700, as in Test No. 7, the complex viscosity was too high, making it difficult to administer into the interdental papilla, and the composition was not suitable for interdental papilla reconstruction.

[0100] Confirmation of interdental papilla reconstruction rate depending on the dosage of hyaluronic acid gel

[0101] Test No. 6, which showed the best interdental papilla reconstruction rate in Experimental Example 1, was injected into the apex of the interdental papilla using a syringe with a 30G needle equipped with an autoinjector.

[0102] To confirm the rate of interdental papilla reconstruction depending on the amount of hyaluronic acid gel administered, the total amount administered was set to 0.005cc, 0.01cc, 0.025cc, 0.05cc, 0.1cc, and 0.2cc, and each was administered in five doses (for example, if the total amount administered was 0.005cc, five doses of 0.001cc each were administered).

[0103] The results confirmed that the rate of interdental papilla reconstruction increased in proportion to the total dose. Furthermore, when the total dose exceeded 0.025cc, the increase in the rate of interdental papilla reconstruction was slight, and there was a possibility of an increased risk of side effects (see Figure 2).

[0104] This confirmed that the total amount of hyaluronic acid gel administered to maximize the rate of interdental papilla reconstruction was 0.025 cc. Experimental Example 3

[0105] Confirmation of interdental papilla reconstruction rate (%) by single dose per unit area

[0106] The area of ​​hyaluronic acid gel administered is 0.25 mm 2 , 1.0mm 2 , 4.0mm 2 , 9.0mm 2 The injection volume per area was set at 0.001cc, 0.002cc, and 0.005cc, and the injection was administered five times using a 30G needle syringe equipped with an autoinjector. The injection points (the injection points) can be seen in Figure 3.

[0107] As a result, as can be seen in Table 2 below, the best interdental papilla reconstruction rate was confirmed when the single dose per unit area was 0.005cc. 2 The most improved interdental papilla reconstruction rate was observed when

[0108] [Table 2]

[0109] The above description focuses on the embodiments, but these are merely examples and do not limit the present invention. Those skilled in the art will understand that various modifications and applications not exemplified above are possible within the scope of the essential characteristics of the present invention. For example, each component specifically illustrated in the examples can be modified and implemented. Furthermore, differences related to such modifications and applications should be construed as being included within the scope of the present invention as defined by the appended claims.

Claims

1. A method for reconstructing an interdental papilla, comprising: The method comprises: administering a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof to the gums; A method for reconstructing interdental papilla, wherein the composition comprises a composition having a complex viscosity of 250 Pa·s to 850 Pa·s.

2. The administering step comprises:

10. The method for reconstructing interdental papillae according to claim 1, comprising administering 0.005 cc to 0.05 cc of the composition.

3. The administering step comprises:

2. The method for reconstructing interdental papillae according to claim 1, comprising administering 0.001 cc to 0.01 cc of the composition 1 to 10 times.

4. The administering step comprises: The composition is mixed with 0.1 mm ２ ~4mm ２ 2. The method for reconstructing interdental papillae according to claim 1, comprising administering the composition to an area of ​​the gingiva.

5. The method of claim 1 , wherein the composition comprises a gel formulation.

6. The method for reconstructing an interdental papilla according to claim 1, wherein the interdental papilla reconstruction rate represented by the following formula (A) is 70% or more. [Equation 1]

7. 2. The method for reconstructing an interdental papilla according to claim 1, wherein the composition is administered using a 25G to 35G needle.

8. The administration step comprises:

2. The method for reconstructing an interdental papilla according to claim 1, comprising administering the composition to a site 1 mm to 3 mm below the apex of the interdental papilla.

9. The method for reconstructing an interdental papilla according to claim 1 , further comprising a molding step.

10. The method comprises: The method for reconstructing interdental papillae according to claim 1, which comprises performing the method at intervals of 2 to 4 weeks.

11. A composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof; An interdental papilla reconstruction kit comprising: a treatment instruction manual describing the method for reconstructing interdental papilla according to any one of claims 1 to 10.

Images